Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Summary

This trial is being conducted to assess the effects of Rotigotine over Placebo on improvement of Apathy and motor symptoms in subjects with early-stage and advanced stage idiopathic Parkinson´s Disease.

Timeline

Start

2013-02

Primary completion

2014-01

Completion

2014-03

Outcome

Mixed primary results

registry Placebo vs Rotigotine, Low Dose; p = 0.977; Least Square Mean 0.04 (95% CI -2.42 to 2.50); ANCOVA NCT01782222 ↗

registry Placebo vs Rotigotine, Low Dose; p = 0.005; Least Square Mean -7.29 (95% CI -12.30 to -2.28); ANCOVA NCT01782222 ↗

Publications

• Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease. BMC Neurol. 2016 Jun 7;16:90. doi: 10.1186/s12883-016-0610-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotigotine	Unknown	2 mg	Other
Subject	Rotigotine	Unknown	4 mg	Other
Subject	Rotigotine	Unknown	6 mg	Other
Subject	Rotigotine	Unknown	8 mg	Other
Subject	Rotigotine	Unknown	16 mg	Other

Indications